Chinese innovative medical device manufacturers are accelerating their expansion into Europe as government anti-corruption measures and pricing pressures reduce domestic procurement opportunities.
- Chinese hospital purchases of medical devices fell sharply due to anti-corruption efforts.
- Jenscare Scientific received EU certification for its innovative heart valve device.
- Europe offers growth but also presents regulatory and protectionism hurdles.
What happened
Chinese medical device makers are confronting a challenging domestic market as government-backed hospital purchases declined by about 12% year-on-year in the first five months of 2026. This drop is largely attributed to an intensified anti-corruption campaign targeting long-standing practices where sales representatives offered kickbacks to hospital officials. The crackdown, ongoing since 2023 and accelerating in April 2026, has squeezed revenues for major players such as Mindray and Snibe.
Amid this environment, companies like Jenscare Scientific have pivoted focus towards Europe. Jenscare’s LuX-Valve Plus, a minimally invasive heart valve replacement device, recently received CE certification under the EU’s updated Medical Device Regulation, enabling sales across the region. This development marks a significant milestone in Jenscare’s international strategy as it seeks to diversify revenue sources amid reduced domestic demand and fierce competition.
Why it matters
China’s domestic medical device market is heavily dependent on public hospitals, which manage about 84% of patient visits. The anti-corruption measures have therefore directly disrupted the main procurement channels for medical equipment manufacturers. The resulting pricing pressure and regulatory scrutiny have compelled many companies to explore overseas markets to sustain growth.
European governments are themselves under fiscal pressure, prompting cost containment measures such as Germany’s recent healthcare savings bill targeting €18.8 billion in cuts by 2027. This creates an opportunity for Chinese firms, whose devices often offer better cost-performance ratios than local competitors. However, Chinese companies still face higher prices abroad and growing protectionism, including the EU’s International Procurement Instrument that bans Chinese firms from bidding on public contracts above €5 million.
What to watch next
Additionally, the evolving landscape of European trade policies and procurement rules will impact Chinese firms’ market access. While current restrictions are limited in scope, increased protectionism or preferential treatment for local suppliers could hinder expansion. The pace and scale of overseas revenue growth for companies like Mindray, which saw over 25% revenue growth in Europe in Q1 2026, will also be critical indicators of success in this strategic shift.